Publications

CLARIOstar® determines activity of a moss-produced human acid alphaglucosidase (GAA) in a fl uorescence-based assay

Berg B, Fischer A, Haessler F, Dabrowska-Schlepp P, Maurer F, Tintelnot S. 2019. CLARIOstar® determines activity of a moss-produced human acid alphaglucosidase (GAA) in a fl uorescence-based assay. BMG LABTECH. 339: Ortenberg. 

https://www.bmglabtech.com/clariostar-determines-activity-of-a-moss-produced-human-acid-alpha-glucosidase-in-a-fluorescence-based-assay/

Single‐Use Processing as a Safe and Convenient Way to Develop and Manufacture Moss‐Derived Biopharmaceuticals

Niederkrueger H, Busch A, Dabrowska-Schlepp P, Krieghoff N, Schaaf A, Frischmuth T. 2019. Single-Use Processing as a Safe and Convenient Way to Develop and Manufacture Moss-Derived Biopharmaceuticals. In: Eibl R, Eibl D, editors. Single-Use Technology in Biopharmaceutical Manufacture. 2nd ed. Hoboken, NJ: Wiley. p. 311-318.

https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119477891.ch28

 

Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease

Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2019. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. Jornal of Inherited Metabolic Disease. 42(3): Hoboken, NJ. 

https://onlinelibrary.wiley.com/doi/full/10.1002/jimd.12052

Real-Time VCD Monitoring of Moss for Therapeutic Protein Production

Koch J, Mueller M, Niederkrueger H. 2018. Real-Time VCD Monitoring of Moss for Therapeutic Protein Production. Hamilton. Bonaduz.

https://www.hamiltoncompany.com/process-analytics/case-studies/app-note-real-time-vcd-monitoring-of-moss-for-therapeutic-protein-production#top

 

Host Cell Proteome of Physcomitrella patens Harbors Proteases and Protease Inhibitors under Bioproduction Conditions

 

 

Pharmacokinetics, pharmacodynamics, and safety of moss agalactosidase A in patients with Fabry disease

Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2018. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. Molecular Genetics and Metabolism. 123(2): Cambridge. 

https://www.sciencedirect.com/science/article/abs/pii/S1096719217309241?via%3Dihub

 

Treatment of experimental C3 Glomerulopathy by human complement factor H produced in glycosylation-optimized Physcomitrella patens

Haeffner K, Parsons J, Bohlender L, Hoernstein S, Niederkrueger H, Fode B, Busch A, Krieghoff N, Koch J, Schaaf A, Frischmuth T, Zipfel P, Pohl M, Reski R, Decker E, Michelfelder S. 2017. Treatment of experimental C3 Glomerulopathy by human complement factor H produced in glycosylation-optimized Physcomitrella patens. Molecular Immunology. 89: Oxford.

https://www.sciencedirect.com/science/article/pii/S0161589017302237

Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders

Michelfelder S, Parsons J, Bohlender L, Hoernstein S, Niederkrueger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel P, Reski R, Decker E, Haeffner K. 2017. Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders. Journal of the American Society of Nephrology. 28(10): Wahington. 

 

Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.

Meng X-L, Day T, McNeill N, Ashcraft P, Frischmuth T, Cheng S, Liu Z, Shen J, Schiffmann R. 2016. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice. Journal of Inherited Metabolic Disease. 39(3): Hoboken, NJ. 

 

 

Development of a Novel Host-Cell Protein Assay: Supporting the Physcomitrella patens Expression System

Dabrowska-Schlepp P, Sommerschuh S, Knappenberger M, Niederkrueger H, Gliese N, Schaaf A. 2016. Development of a Novel Host-Cell Protein Assay: Supporting the Physcomitrella patens Expression System. BioProcess International.14(2): Boston.

 

 

Biopharmazeutika durch pflanzliche Produktion in geschlossenen Systemen

Niederkrueger H, Schaaf A, Koch C, Pultar T. 2015. Biopharmazeutika durch pflanzliche Produktion in geschlossenen Systemen. TechnoPharm. 5(5): Mainz.

 

 

Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice

Shen J-S, Busch A, Day T, Meng X-L, Yu C, Dabrowska-Schlepp P, Fode B, Niederkrueger H, Forni S, Chen S, Schiffmann R, Frischmuth T, Schaaf A. 2016. Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. Journal of Inherited Metabolic Disease. 39(2): Hoboken, NJ. 

 

 

Suspension Culture of Plant Cells Under Phototrophic Conditions

Holger Niederkrueger, Paulina Dabrowska-Schlepp, Andreas Schaaf (2014)
Wiley-VCH Verlag, Meyer, H.-P. / Schmidhalter, D. (eds.): Industrial Scale Suspension Culture of Living Cells (978-3-527-33547-3), 8

Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants

Parsons, J., Altmann, F., Arrenberg, C. K., Koprivova, A., Beike, A. K., Stemmer, C., ... Decker, E. L. (2012)
Plant Biotechnology Journal, 10(7), 851–861. doi:10.1111/j.1467-7652.2012.00704.x

Production of biologically active recombinant human factor H in Physcomitrella

Annette Buettner-Mainik, Juliana Parsons, Hanna Jerome, Andrea Hartmann, Stephanie Lamer, Andreas Schaaf, Andreas Schlosser, Peter F. Zipfel, Ralf Reski and Eva L. Decker
Plant Biotechnology Journal (2010), 1–11

Therapeutische Antikörper mit optimierten Effektorfunktionen – Neueste Strategien in der Krebsimmuntherapie

Gorr G, Kircheis R. 2007. Therapeutische Antikörper mit optimierten Effektorfunktionen – Neueste Strategien in der Krebsimmuntherapie. Deutsche Zeitschrift für Klinische Forschung (DZKF). 11: Kulmbach. 

 

Proteinherstellung: Bryotechnologie – innovatives Tool für rekombinante Proteinproduktion

Gorr G. 2007. Proteinherstellung: Bryotechnologie – innovatives Tool für rekombinante Proteinproduktion. 11: Heidelberg. 

 

 

High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fucT Delta-xylT mutant

Weise A, Altmann F, Rodriguez-Franco M, Sjoberg ER, Bäumer W, Launhardt H, Kietzmann M, Gorr G. 2007. High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fucT Delta-xylT mutant. Plant Biotechnological Journal. 5(3): Hoboken, NJ. 

 

 

In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system

Schuster M., Jost W., Mudde GC., Wiederkum S., Schwager C., Janzek E., Altmann F., Stadlmann J., Stemmer C., Gorr G.(2007)
Biotechnology Journal 2, 700-708

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies

Nechansky, A., Schuster, M., Jost, W., Siegl, P., Wiederkum, S., Gorr, G. and Kircheis, R. (2007)
Molecular Immunology 44, 1826-1828

Glycosylation of recombinant proteins in plants

Gorr, G. and Altmann, F. (2006)
Vol. 2: 345-374. In Medicinal Plant Biotechnology (Eds. Kayser, O. and Quax, W.) Wiley-VCH

A fast and flexible PEG-mediated transient expression system in plants for high level expression of secreted recombinant proteins

Baur, A., Kaufmann, F., Rolli, H., Weise, A., Luethje, R., Berg, B., Braun, M., Baeumer, W., Kietzmann, M., Reski, R. and Gorr, G. (2005)
Journal of Biotechnology 119, 332-342

Glycosylation design in transgenic moss for better product efficacy

Gorr, G. and Jost, W. (2005)
Bioprocessing Journal 4, 26-30

Enhanced recovery of a secreted recombinant human growth factor by stabilising additives and by coexpression of human serum albumin in the moss Physcomitrella patens

Baur, A., Reski, R. and Gorr, G. (2005)
Plant Biotechnology Journal 3, 331-340

Glyco-engineering of moss lacking plant-specific sugar residues

Huether, C.M., Lienhart, O., Baur, A., Stemmer, C., Gorr, G., Reski, R. and Decker, E.L. (2005)
Plant Biology, 7, 292-299

Isolation and characterisation of three moss derived beta-tubulin promoters suitable for recombinant expression

Jost, W., Link, S., Horstmann, V., Decker, E.L., Reski, R. and Gorr, G. (2005)
Current Genetics 47, 111-120

Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans

Koprivova, A., Stemmer, C., Altmann, F., Hoffmann, A., Kopriva, S., Gorr, G., Reski, R., and Decker, E. L. (2004)
Plant Biotechnology Journal 2, 517-523

N-Glycosylation in the moss Physcomitrella patens is organized similarly to higher plants

Koprivova, A., Altmann, F., Gorr, G., Kopriva, S., Reski, R. and Decker, E.L. (2003)
Plant Biology 5, 582-591

Moss – An Innovative Tool for Protein Production

Decker, E.L., Gorr, G. and Reski, R. (2003)
BIOforum Europe 2, 96-97

Tight control of growth and cell differentiation in photoautotrophically growing moss (Physcomitrella patens) bioreactor cultures

Hohe, A., Decker, E.L., Gorr, G., Schween, G. and Reski, R. (2002)
Plant Cell Reports 20, 1135-1140